GlassScriptPhysician profile
Jenifer Drummond
NPI 1548425085
$1,042.46
in general payments reported to CMS, 2019-2025
19 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2022: $25.00 · 2023: $209 · 2024: $172 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $252.70 | 2019 | |
| Inari Medical, INC. | $155.02 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Allergan, INC. | $119.74 | 2019 | |
| Lilly USA, LLC | $83.56 | 2023-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $71.54 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $48.71 | 2024-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $42.00 | 2024-2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $39.76 | 2024 | Gemtesa |
| Exact Sciences Corporation | $36.48 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $33.76 | 2024-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Organogenesis INC. | $25.00 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $22.03 | 2025 | Neffy |
| Amneal Pharmaceuticals LLC | $20.63 | 2025 | Unithroid |
| Pfizer INC. | $17.71 | 2024 | |
| Axsome Therapeutics, INC. | $17.44 | 2023 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $14.55 | 2025 | Contrave |
| Shield Therapeutics INC | $14.48 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.89 | 2023 | Quviviq |
| Intra-Sana Laboratories | $13.46 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenifer Drummond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.